Pregled bibliografske jedinice broj: 1237452
DEHYDRATECH-CBD DIETARY SUPPLEMENT AND EFFECT ON HYPERTENSION
DEHYDRATECH-CBD DIETARY SUPPLEMENT AND EFFECT ON HYPERTENSION // Abstracts of the 4th International Congress on Food Safety and Quality “One Health” / Kolarić, Branko ; Krivohlavek, Adela ; Bošnir, Jasna ; Šikić, Sandra (ur.).
Zagreb, 2022. str. 50-50 (poster, recenziran, sažetak, znanstveni)
CROSBI ID: 1237452 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
DEHYDRATECH-CBD DIETARY SUPPLEMENT AND EFFECT ON
HYPERTENSION
Autori
Batinić, Ana ; Kuret, Sendi ; Matana, Antonela ; Sutlović, Davorka ; Dujić, Željko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 4th International Congress on Food Safety and Quality “One Health”
/ Kolarić, Branko ; Krivohlavek, Adela ; Bošnir, Jasna ; Šikić, Sandra - Zagreb, 2022, 50-50
Skup
4 međunarodni skup o sigurnosti hrane i kvaliteti hrane: Jedno zdravlje
Mjesto i datum
Dubrovnik, Hrvatska, 09.11.2022. - 12.11.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Recenziran
Ključne riječi
blood pressure ; Canabidiol ; food suplements ; GC/MS method ; liver metabolism
Sažetak
Cannabidiol (CBD) is a bioactive cannabinoid with non-psychotropic effects and is consumed as food supplement by millions of people today. DehydraTECH-CBD is patented capsule formulation (developed by Lexaria Bioscience Corp.) that increases the bioabsorption of the active content due to its enhanced lipophilic composition by bypassing (or reducing) first-pass liver metabolism. It was conducted as a double-blinded, placebo- controlled, cross-over pilot study in which 24 eligible volunteers (12 males and 12 females) were recruited and completed all experimental parts. The aim of that study was to extend the findings of DehydraTECH-CBD on cardiovascular system in humans with mild or moderate untreated hypertension. Each participant received in a randomized and double-blinded order CBD or DehydraTECH-CBD (12 capsules with 300 mg of active substance). Blood pressure and heart rate were measured in triplicate every 10 minutes throughout the study. Three venous blood samples were taken: at baseline and in the 120th and 180th minutes. CBD concentration was determined by a GC-MS/MS system. Our results have showed that in the subset of volunteers who were Stage 2 hypertensive, peak systolic BP reductions from baseline were observed of as much as approximately 13 mmHg by the 50- minute time point with DehydraTECH-CBD, and systolic BP remained depressed throughout almost the entire 3-hour duration of the study. We can conclude that DehydraTECH technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Split,
Sveučilište u Splitu Sveučilišni odjel zdravstvenih studija
Profili:
Davorka Sutlović
(autor)
Antonela Matana
(autor)
Sendi Kuret
(autor)
Ana Batinić
(autor)
Željko Dujić
(autor)